Hit to Lead Process Explained: From Confirmed Hit to Lead Series

The hit to lead process is the stage of drug discovery that turns a confirmed hit, a compound that reproducibly engages the target, into a lead series, a set of related compounds with the potency, selectivity, and drug-like properties needed to justify entering lead optimization. Between a hit's first signal and a lead's promise lies the discipline of confirming, improving, and filtering, and that discipline is what hit to lead is.

Most screening hits do not survive the journey, and the ones that do survive it changed substantially along the way. This guide explains the stages, the filters, and the criteria that mark the transition from hit to lead, for readers who need to understand the process rather than run it.

The Stages in One Overview

The stages form a funnel: confirmation removes artifacts, assessment removes untractable chemistry, expansion builds the structure-activity relationship, and lead declaration applies the formal criteria. Each stage is a deliberate filter, and the process's value is that weak candidates fail early and cheaply rather than deep in optimization.

Hit Confirmation: Separating Signal From Artifact

Primary screens produce candidates that include artifacts: compounds that aggregate, interfere with the assay's readout, or contain impurities responsible for the signal. Confirmation re-tests the hit in the original assay, checks the compound's purity and identity, and runs a dose-response curve to show the activity is concentration-dependent and reproducible.

Confirmation is the credibility gate, and its rigor decides everything downstream: pursuing an artifact wastes the team's chemistry effort and poisons the structure-activity relationship with noise. The confirmed hit is a compound that survives re-testing, which is a much stronger claim than "active in the screen," and the confirmation data is the baseline against which every later improvement is measured.

Hit Assessment: Choosing Which Hits Deserve Chemistry

Assessment triages confirmed hits by their promise: potency and selectivity against the target, chemical tractability for analog synthesis, and early signals about the compound's behavior in solution and in cells. A potent but untractable scaffold stalls at the first synthesis attempt, while a modest but tractable scaffold can be improved, so assessment weighs potential rather than raw potency alone.

The triage also considers the competition: hits that resemble known problem chemotypes, compounds with a history of toxicity or assay interference, are deprioritized before chemistry is spent on them. The assessment's output is the shortlist of hits that justify the next stage's investment, and the reasons for inclusion and exclusion are recorded, because the shortlist is a decision the program may need to revisit.

Hit Expansion: Building the Structure-Activity Relationship

Expansion synthesizes analogs around each promising hit and measures how structural changes move activity, which builds the structure-activity relationship, the map of which parts of the molecule tolerate change and which drive potency. The SAR map is the stage's core deliverable: it shows the program where improvement is possible and guides the design of each next round.

Expansion is iterative and data-driven, each round's results shaping the next round's designs, and the quality of the records determines how fast the iteration converges. An analog's activity, its structural change, and the assay conditions belong together in the record, because the SAR map is only as reliable as the data beneath it. For teams that want analog records and assay data connected, the Zettalab workspace links structured experiment records with team file storage.

The Filters: Potency, Selectivity, and Early Drug-Like Properties

Alongside potency, the process applies filters that anticipate what a lead must become. Selectivity against related targets matters because an unselective compound's biology is confounded from the start. Early pharmacokinetic and solubility measurements catch compounds that are potent in vitro but will never reach their target in an organism. Chemical stability and synthetic accessibility keep the series manufacturable and scalable.

These filters are applied early and repeatedly, because each represents a class of failure that becomes more expensive to fix the later it is found. The process's logic is to surface the disqualifying property while the series is still cheap to redesign, which is why hit to lead runs potency, selectivity, and early ADME properties in parallel rather than in sequence.

Lead Declaration: The Criteria That Close the Stage

A hit becomes a lead when it meets the program's declared criteria: a defined potency level, acceptable selectivity, tractable chemistry, and no disqualifying property in the early filters. The criteria are written down in advance, because the declaration should be a measured comparison against a standard, not an enthusiasm.

The declared lead enters optimization as a series, a family of related compounds sharing the validated scaffold, with the SAR map as its operating manual. The transition matters because it concentrates the program's chemistry on chemistry that has earned it: the lead series is the point where the project's risk profile changes from "is there a molecule" to "can we make the molecule a drug." For teams that want the computational and experimental data behind these decisions connected, the Zettalab workspace links structured experiment records with team file collaboration, so the SAR data, assay evidence, and filter results stay attached to the compound series they describe.

FAQ

What is the difference between a hit and a lead in drug discovery?

A hit is a compound that shows reproducible, concentration-dependent activity against the target in early screening, while a lead is a compound or series that has passed the program's declared criteria for potency, selectivity, and tractability, and is worth entering optimization. The difference is validation: a hit is a confirmed signal, a lead is a validated starting point with a working SAR map and no disqualifying property.

What happens during hit confirmation?

The hit is re-tested in the original assay, its purity and identity are verified, and a dose-response curve confirms the activity is concentration-dependent and reproducible. Confirmation exists to remove artifacts: aggregating compounds, assay interferents, and impurity-driven signals. A confirmed hit is a compound that survives re-testing, which is a much stronger claim than being active in the screen.

How is hit to lead different from lead optimization?

Hit to lead turns a confirmed screening hit into a validated lead series through confirmation, assessment, analog expansion, and filtering, while lead optimization takes the lead series and refines it toward a development candidate, improving potency, pharmacokinetics, and safety in parallel. Hit to lead answers "is there a worthy starting point," and lead optimization answers "can this starting point become a drug."

What criteria promote a hit to lead?

The program's declared criteria, written in advance: a defined potency level, acceptable selectivity against related targets, chemical tractability and synthetic accessibility, and no disqualifying property in the early filters such as poor solubility or stability. The declaration compares the compound against the standard rather than against enthusiasm, which is what makes the transition a decision rather than a hope.

Why is selectivity checked during hit to lead?

Because an unselective compound's biology is confounded from the start: activity against related targets mixes effects in every experiment and makes the structure-activity relationship uninterpretable. Checking selectivity early, when the series is cheap to redesign, avoids spending chemistry on a scaffold whose core problem is structural. The filter belongs in the early stages for the same reason all filters do: failures cost more the later they are found.

What is the SAR map and why does it matter?

The structure-activity relationship map shows how structural changes to the molecule move its activity: which positions tolerate modification, which drive potency, and which break the compound. It is built during hit expansion from the recorded pairing of each analog's structure with its measured activity. The map is the series' operating manual, guiding each next round of design, and its reliability depends on the quality of the records beneath it.

Conclusion

Hit to lead is the funnel that separates screening's signals from optimization's starting points: confirmation removes artifacts, assessment removes untractable chemistry, expansion builds the SAR map, and declared criteria close the transition to a lead series. The process's discipline is filtering early and cheaply, so that the chemistry spent in optimization is spent on chemistry that has earned it. To connect the experimental and computational evidence behind these decisions, explore Zettalab's cloud-based R&D lab platform.